FDA clears Idera psoriasis therapy trial medicine Business Review Idera Pharmaceuticals has received notification from the Food and Drug Administration (FDA) to transfer on with a state of matter 2 clinical trial of IMO-3100 in patients with psoriasis . IMO-3100 is a dual antagonist of Toll-like receptor (TLR) vii and TLR9, ... and more » Link To Article
No comments:
Post a Comment